Will Failed Hepatitis Trials Affect Bristol-Myers Squibb Foundation Grants?

When Bristol-Myers Squibb, the company, closed on its $2.5 billion bid to purchase Inhibitex, a small developer of what seemed to be a promising hepatitis C drug, the Bristol-Myers Squibb Foundation made nearly $1.7 million in grants toward hepatitis B and C prevention and care in China and India. A short time later, all clinical trials of Inhibitex were scrapped. Will this affect the Bristol-Myers Squibb Foundation's commitment to hepatitis B and C?
Read More

Will the Bristol-Myers Squibb Foundation Disarm India's Diabetes Time Bomb?

There is a diabetic epidemic in India, and the Bristol-Myers Squibb Foundation is working hard to reverse this deadly trend by awarding $1.6 million in grants to five Indian organizations through its Together on Diabetes program. Launched in 2010, the Together on Diabetes program is a five year, $100 million initiative to help improve the outcomes of people living with Type 2 diabetes in the United States, China and India. 

Read More